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Summary 
Background and purpose The presumed safety of paracetamol in high cardiovascular risk patients 
has been questioned. We determined whether paracetamol or ibuprofen use is associated with major 
cardiovascular events (MACE) or major bleeding in 19,120 patients with recent ischemic stroke or 
transient ischemic attack (TIA) of mainly atherothrombotic origin included in the PERFORM trial. 
Methods We performed two, nested case-control analysis (2153 cases with MACE during trial follow- 
up and 4306 controls matched on Essen Stroke Risk Score; 809 cases with major bleeding matched 
with 1616 controls), and a separate time-varying analysis.Results12.3% were prescribed paracetamol 
and 2·5% ibuprofen. Median duration of treatment was 14 (IQR 5–145) days for paracetamol and 9 
(5–30) days for ibuprofen. Paracetamol, but not ibuprofen, was associated with increased risk of a 
MACE (odds ratio [OR] 1·21, 95% confidence interval [CI] 1·04–1·42) or a major bleeding (OR 1·60, 
95% CI 1·26–2·03), with no impact of daily dose and duration of paracetamol treatment. Time-varying 
analysis found an increased risk of MACE with both paracetamol (HR 1·22, 95% CI1·05–1·43) and 
ibuprofen (HR 1·47, 95% CI 1·06–2·03) and of major bleeding with paracetamol (HR 1·95, 95% CI 
1·45–2·62) 
Conclusion There was a weak and inconsistent signal for association between paracetamol or 
ibuprofen and MACE or major bleeding, which may be related to either a genuine but modest effect of 
these drugs, or to residual confounding. 
Clinical Trial Registration InformationISRCTN66157730 
URL: 
http://www.isrctn.com/ISRCTN66157730?totalResults=5&pageSize=10&page=1&searchType=basic-
search&offset=3&q=&filters=conditionCategory%3ACirculatory+System%2CrecruitmentCountry%3AT
aiwan%2CrecruitmentCountry%3AAustria&sort= 
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Introduction 
The association between non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk is 
well established, particularly in high-risk populations.1Paracetamol (acetaminofen) is the most widely 
used analgesic and antipyretic worldwide.2 It is commonly accepted that it has a better safety profile 
than NSAIDs, and thus it is usually the treatment of choice in many medical conditions. In patients with 
a high cardiovascular risk, recommendations state that paracetamol should be chosen over NSAIDs.3 
Recently, this assumed safety profile has been questioned. First, Hinz et al. found that paracetamol 
produces a substantial selective cyclooxygenase 2 (COX-2) inhibition, to a degree comparable to non-
selective NSAIDs and selective COX-2 inhibitors.4 Considering the vascular risk associated with COX-
2 inhibitors, these results suggest that the presumed safety of paracetamol should be revisited.5-7In 
addition, chronic paracetamol consumption maybe related to hypertension, a major vascular risk 
factor.8-10Indeed some studies have shown an increased risk of cardiovascular events and stroke in 
patients treated with paracetamol, particularly in high-dose users.10, 11 Nevertheless, the hypothesis of 
a paracetamol-associated cardiovascular risk remains controversial. Paracetamol intake was not 
associated with an increase in stroke rate in a recent population-based case-control study, nor to 
myocardial infarction in other studies.12-14 In an acute stroke setting, paracetamol treatment to control 
mild-to-moderate hyperthermia (37–39°C) seemed to be associated with a better final outcome, 
reducing disability at 3months according to the modified Rankin scale.15Although there is a more 
commonly accepted belief that other NSAIDs, such as ibuprofen, have a higher vascular risk, there are 
still conflicting data in the literature. While some authors claim that ibuprofen intake is associated with 
an increase in vascular risk,16 others have found no such association.12, 13NSAIDs associated bleeding 
risk is well known, particularly of a gastrointestinal origin.16 Their use represents an independent risk 
factor in patients with an antithrombotic treatment, even when prescribed for a short term.17 
Differences between NSAIDs have been noted, probably related to a variable COX-1 inhibition and 
different half-lives, but while some authors claim that Ibuprofen could have a lesser risk, others have 
found a similar bleeding risk compared to other NSAIDs.16, 18Paracetamol has an excellent 
gastrointestinal tolerability and safety profile concerning bleeding complications.19,20 It is hence again 
the preferred analgesic in cases of an elevated bleeding risk. 
PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with 
teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack) was a 
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randomised, double-blinded clinical trial comparing the efficacy of terutroban, a selective 
prostaglandin-thromboxane antagonist, against aspirin for the prevention of cardiovascular events 
after a cerebral vascular event.21By analysing paracetamol and ibuprofen use in patients who were all 
on a background of antiplatelet therapy, we aimed to clarify whether there was an attributable 
cardiovascular risk associated with paracetamol or ibuprofen use in this high vascular risk population. 
 
 
Methods 
Selection of cases and controls for the nested case-control study 
Two nested case-control studies were performed. One addressed cardiovascular events (death, 
myocardial infarction or stroke) and a second, life threatening (defined by a fatal outcome, a reduction 
in haemoglobin of 50 g/L or more, symptomatic intracranial haemorrhage or transfusion of 4 units or 
more of red blood cells) and major bleeding events (defined by a significantly disabling bleeding, an 
intraocular bleeding leading to significant loss of vision, a transfusion of 3 units or less of red blood 
cells, or needing hospital admission or surgery). The same procedure was performed for both nested-
case control study. 
We defined cases as those with a first occurrence of a major cardiovascular (or major bleeding) event 
after randomisation in the PERFORM trial. Over a 4-year follow-up, 2153 cardiovascular events and 
809 major bleedings were recorded. The date of the event was considered as the index date.  
Based on incidence density sampling, we selected up to two control subjects for each case by random 
sampling from all members of the study cohort who were alive before the day the case subject had the 
event. With this design, all cohort members were eligible to serve as controls for more than one case 
subject; and case subjects before the event were eligible to serve as controls for other case subjects 
who had an earlier event. Control subjects were individually matched to each case subject by Essen 
stroke risk score (ESRS) (+/- 1), comprising age, arterial hypertension, diabetes mellitus, previous 
myocardial infarction, other cardiovascular disease, peripheral artery disease, smoking, previous 
transient ischaemic attack (TIA) or ischaemic stroke, in addition to qualifying event and duration of 
follow-up. Since individual components of ESRS were available for all of patients, no imputation to 
handle missing data was done before matching. Thus, all controls were alive, not previously 
diagnosed as having a recurrent major cardiovascular event (or major bleeding), and had an equal 
 6 
duration of follow-up at the risk set date. The index date of controls was defined as the date of event of 
their matched case. In the analysis, estimates of paracetamol or ibuprofen exposure for each control 
subject were truncated at the date of the event of the matched case subject. 
Exposure definition 
For all cases and controls, we obtained information on paracetamol and ibuprofen use between the 
date of enrolment in the study and the index date. We had information about the timeline of the 
prescription and the dose. Also patients were asked to record the frequency of their use. They were 
classified into one of three groups: no use; occasional use; and daily use (several intakes for >1 days). 
Statistical analysis 
Data are expressed as mean ± standard deviation or median (interquartile range [IQR]) for continuous 
variables and count (percentage) for qualitative variables. The same analyses were performed for both 
the nested case-control studies.  
Baseline characteristics were described and compared between the cases and ESRS matched 
controls by using the McNemar test for binary variables and the paired Student t test or the Wilcoxon 
signed rank test for continuous variables. 
We compared the paracetamol or ibuprofen exposures between cases and controls using conditional 
logistic regression for matched sets with and without adjustment for history of paracetamol or 
ibuprofen prior randomization. Using patients with no-exposure as reference, we derived from this 
model, the odds ratios (ORs) with their corresponding 95% confidence intervals (CIs) as effect size 
measure. 
A second analysis was performed using a time-varying Cox regression analysis by using all 
paracetamol(or ibuprofen) exposure status recorded at baseline and at each follow-up visit. This 
secondary sensitivity analysis, attempted to account for change in paracetamol (or ibuprofen) use 
status over time by including a time-dependent covariate into the Cox model with and without 
adjustment for the ESRS and history of paracetamol or ibuprofen prior randomization. 
Finally we performed a sensitivity analysis restricted to patients with aspirin treatment at randomisation  
Statistical testing was conducted at the 2-tailed α-level of 0.05. Data were analyzed using the SAS 
software version 9.3 (SAS Institute, Cary, NC). 
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Results 
Nested case-control study 
 
 Major cardiovascular event 
We identified 2153 cases with a major cardiovascular (cardiac death, myocardial infarction or stroke) 
event and 4306 matched controls. The baseline characteristics are described in Table 1. The mean 
age of cases was 69 years and 70 years for controls.13.7% of cases used paracetamol at the index 
date compared with 11.7% of controls. Paracetamol treatment was associated with an increased risk 
of major cardiovascular events (OR 1·21, 95% CI 1·04–1·42).  
Patients who used paracetamol daily had a higher risk of major cardiovascular events but the OR was 
not significant (adjusted-OR 1·20, 95% CI 0·89–1·63).In this group, the median duration of 
paracetamoltreatmentwas14 (IQR 5–145) days. No effect was found for daily dose and duration of 
treatment. The OR for a dose of ≥3000 mg/day was not significant (Fig. 1).  
Patients who used ibuprofen had no significant increase in the risk of major cardiovascular events (OR 
1·03, 95% CI 0·73–1·34) and there was no significant association with duration or dose of ibuprofen 
treatment (Fig. 2). The median treatment duration for patients with a daily use was 9 (IQR5–30) days. 
In sensitivity analysis restricted to patients with aspirin treatment at randomisation(1047 cases and 
2094 matched control), a similar association between paracetamol and major cardiovascular event 
was found (adjusted OR, 1.36, 95% CI 1.11-1.67).However, for ibuprofen, an association with 
increased risk of major cardiovascular events was close to significance level (adjusted-OR,1.43, 95% 
CI 0.99-2.05).  
 
 Major bleeding 
They were 809 cases with major bleeding matched with 1616 controls. Supplementary table I shows 
sites of major bleedings. The mean age was 69 years for cases and 68 years for controls and 60% of 
cases were men compared with 62% of controls. 18.4% of cases were paracetamol users at the index 
date, compared with 12.3% controls. Paracetamol treatment was associated with major bleeding 
(adjusted-OR 1.60, 95% CI 1.26-2.03, Fig 1). Daily users had a higher risk of major bleeding. In 
addition, the risk of major bleeding increased gradually with the daily dose (P for trend across dose 
levels=0.02, Fig 1). 
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4.8% of cases were ibuprofen users at the index date compared with 3.7% controls. Ibuprofen was not 
associated with major bleeding (Fig 2). We also found no association between dose or duration of 
treatment.  
In sensitivity analysis restricted to patients with aspirin treatment at randomisation (406 cases and 812 
matched controls), paracetamol remained associated with an increase in major bleedings event 
(adjusted OR, 1.58, 95% CI 1.16-2.14). For ibuprofen the association remained not significant 
(adjusted OR, 1.45, 95% CI 0.86-2.44). 
 
Time-varying analysis 
Using all prescriptions of paracetamol or ibuprofen during follow-up, we found an increased risk of 
major cardiovascular events in patients who received paracetamol (HR 1·23, 95% CI 1·05–1·43) or 
ibuprofen (HR 1·42, 95% CI 1·03–1·96). After multiple adjustments, the same results were obtained 
(table 2). For paracetamol, we also found an increased risk among patients who used the drug 
occasionally (Fig. 3).A non-significant increased risk was observed for patients with a dose ≥3000 
mg/d. For ibuprofen, similar to the previous analyses, there was no effect of daily use and no dose 
effect (Fig. 3). 
There was also an increased risk of major bleeding with paracetamol treatment (adjusted-HR 1·95, 
95% CI 1·45–2·62) but not with ibuprofen treatment (adjusted-HR 1·02, 95% CI 0·54–1·90).Daily use 
of paracetamol and ibuprofen was associated with a higher risk of major bleeding (Fig. 3). Also, a 
significant increase risk was observed for patients with a dose ≥3000   
In sensitivity analysis restricted to patients with aspirin treatment at randomisation, only paracetamol 
was associated with an increase in major cardiovascular and major bleeding events (adjusted HRs 
[95%CI]:1.27[1.04-1.55], 1.93[1.46-2.56], respectively).  
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Discussion 
In this high vascular risk population of nearly 20,000 patients with recent ischaemic stroke or TIA, we 
found a weak and inconsistent relationship between paracetamol or ibuprofen prescription and 
recurrent major cardiovascular events or major bleeding. Even if there was an association between 
paracetamol prescription and an increased risk of major cardiovascular events or major bleeding, a 
dose effect was only found in the time-varying analysis and not in the nested case-control analysis, 
and patients who had longer paracetamol prescription showed no increase in the rate of major 
cardiovascular events. The results were not concordant for ibuprofen: in the nested case-control 
analysis there was no association between ibuprofen prescription and the risk of major cardiovascular 
events but this association was significant in the time-varying analysis. The results were consistent 
when only patients randomised to aspirin at baseline were taken into account. Overall, the 
strength of these associations for both paracetamol and ibuprofen was low, making possible that other 
undetected confounding factors explained these weak associations. 
There are some limitations to our study. First, this is a high vascular risk population, and all patients 
were on antiplatelet treatment, so these results cannot be extrapolated to the general population. 
Besides, as previously pointed out, there are possible confounding factors underlying paracetamol 
prescription. Finally, our population was selected for a different purpose and was not homogeneous in 
terms of paracetamol intake, even if we tried to avoid this kind of bias with the case-control design. We 
also performed a propensity score-adjusted analysis and found similar inconsistent results (data not 
shown). The weak association between occasional paracetamol use and cardiovascular events or 
bleeding was possibly confounded by the underlying pathology that justified the prescription. On one 
hand, paracetamol could have been taken for misdiagnosed chest pain related to coronary events. On 
the other, paracetamol prescription is often associated with diseases implying a systemic inflammatory 
response. There is evidence of a relationship between systemic inflammation and stroke 
pathogenesis. Atherosclerosis, a major cause of stroke, is partly an inflammatory disease.22 Besides, 
many inflammatory conditions have been associated with ,stroke.23 Chronic inflammatory diseases, 
such as rheumatoid arthritis, systemic lupus erythematosus, giant-cell arteritis, and atopic dermatitis 
imply an increased risk of stroke.24-26 Finally, an increased risk of both myocardial infarction and stroke 
has been associated with previous infections, especially in the 7 days following a respiratory 
infection.27, 28The unexpected association between paracetamol and major bleeding in our study raises 
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concern about its safety in patients under antithrombotic treatment. Nevertheless there are also some 
confounding factors that should be considered. Most of the major bleeding were of gastrointestinal 
origin or related to a surgical intervention (supplementary data, table 1), Because of its alleged safety 
profile, paracetamol is often prescribed in patients with a pre-existing medical condition implying an 
important bleeding risk and in a postoperative setting as a painkiller, which constitutes an important 
prescription bias. Besides, paracetamol can be also used as a symptomatic treatment for 
gastrointestinal diseases with possible bleeding complications.29 These bias have been already 
underlined by other authors, who found an association with major bleeding when paracetamol was 
prescribed for gastrointestinal discomfort, but not for other indications, like headaches.30, 31 Our 
patients were under antithrombotic treatment, either terutroban or aspirin. If an analgesic or antipyretic 
was needed, their physicians may have chosen paracetamol over NSAIDs in regard of its tolerability. 
Ibuprofen would have been used only in low risk patients, and its use seems safe when used at doses 
of 1200mg/day or lower.32 
In conclusion, there was a weak and inconsistent signal for an association between paracetamol and 
ibuprofen use and major vascular events or major bleedings, which may be related to either a genuine 
but modest effect of paracetamol and ibuprofen or to residual confounding. Given the uncertainty and 
the widespread use of paracetamol, the safety of paracetamol and ibuprofen among patients with 
ischaemic stroke should be elucidated in future randomised studies. 
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Table 1: Characteristics of cases (with major vascular events)and controls. 
 
 Major cardiovascular event  Major bleeding 
 Cases 
(n=2153) 
Controls 
(n=4306) 
 Cases 
(n=809) 
Controls 
(n=1618) 
Demographics      
Age (years) 69·2±8·2 69·7±7·8**  69·2±8·0 68·3±8·0 ** 
Men 1449 (67·3) 2741 (63·7)*  536 (66·3) 1012 (65·4)* 
Body mass index (kg/m2) 27·0±4·3 27·1±4·3  26·6±4·5 27·2±4·3 
Systolic blood pressure (mmHg) 138·3±15·7 138·1±15·8  138·8±15·6 137·8±15·5 
Diastolic blood pressure (mmHg) 79·4±8·5 79·2±8·5  79·4±8·7 79·6±8·4 
Total cholesterol (mmol/L) 4·7±1·2 4·6±1·2  4·5±1·1 4·6±1·2 
Low-density lipoprotein 
cholesterol (mmol/L) 
1·2±0·3 1·2±0·3  1·3±0·4 1·2±0·3 
High-density lipoprotein 
cholesterol (mmol/L) 
2·8±1·0 2·8±1·0  2·7±0·9 2·8±1·0 * 
Risk factor      
Hypertension 1842 (85·6) 3917 (91·0) *  703 (86·9) 1431 (88·4) ** 
Diabetes 742 (34·5) 1623 (37·7)*  234 (28·9) 559 (34·6)* 
Hypercholesterolemia 1025 (47·6) 2145 (49·8)*  395 (48·8) 796 (49·2) 
Current smoker 571 (26·5) 1326 (30·8)*  227 (28·1) 475 (29·4) 
Previous stroke 492 (22·9) 945 (22·0)   161 (19·9) 294 (18·2) 
Previous transient ischaemic 
attack 
185 (8·6) 497 (11·5)*    61 (7·4)  140 (8·7) 
Previous myocardial infarction 312 (14·5) 668 (15·5)    73 (9·0)  150 (9·3) 
Essen stroke risk score 4 (3–5) 3 (3–4)      3 (2–4)     3 (2–4) 
Duration of follow-up (years) 11 (4-19.5) 11 (4-19.5)  12 (5-20) 12 (5-20) 
*<0.005, **<0.05 
Data are number (%), mean±SD, or median (IQR) unless stated otherwise.   
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Figure 1: Effect of paracetamol on risk of major cardiovascular events or major bleedings 
 
Data are number (%) unless otherwise specified. CI=confidence interval; OR=odds ratio. *Adjusted on 
previous use of paracetamol.† Calculated for daily use. One confidence interval were truncated 
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Figure 2. Effect of ibuprofen on risk of major cardiovascular events or major bleedings 
 
Data are number (%) unless otherwise specified. CI=confidence interval; OR=odds ratio. *Adjusted on 
previous use of ibuprofen.† Calculated for daily use. One confidence interval were truncated 
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Table2: Time-dependent HR for paracetamol and ibuprofen and major cardiovascular events or major 
bleeding risks 
 Unadjusted 
HR(95% CI) 
P value Adjusted* 
HR(95% CI) 
P value 
Major cardiovascular event     
Paracetamol 
Ibuprofen 
1·23 (1·05–1·43) 
1·42 (1·03–1·96) 
0·01 
0·03 
1·22 (1·05–1·43) 
1·47 (1·06–2·03) 
0·01 
0·02 
Major bleeding     
Paracetamol 
Ibuprofen 
1·84 (1·48–2·28) 
1·02 (0·54–1·90) 
<0·0001 
0·96 
1·89 (1·52–2·34) 
1·05 (0·56–1·96) 
<0·0001 
0·88 
CI=confidence interval; HR=hazard ratio. *Adjusted on Essen stroke risk score and previous use of 
paracetamol or ibuprofen 
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Figure 3: Major cardiovascular events or major bleedings according to frequency of consumption of 
paracetamol or ibuprofen and to dose of paracetamol or ibuprofen in time-varying analysis  
 
CI=confidence interval; HR=hazard ratio. *Reference. † Calculated for daily use ‡Adjusted on Essen 
stroke risk score and previous use of paracetamol or ibuprofen.Note: there was no cardiovascular and 
bleeding event in the dose class 1500–2999 mg/d. One confidence intervals were truncated 
 
